{
    "clinical_study": {
        "@rank": "137708", 
        "acronym": "Constellation", 
        "arm_group": [
            {
                "arm_group_label": "Timolol Maleate", 
                "arm_group_type": "Active Comparator", 
                "description": "Timolol maleate ophthalmic solution 0.5% administered 1 drop BID once in morning and once in the evening for 4 weeks."
            }, 
            {
                "arm_group_label": "BOL-303259-X", 
                "arm_group_type": "Experimental", 
                "description": "BOL-303259-X topical ophthalmic solution administered 1 drop QD in the evening for 4 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This clinical investigation is being performed to compare the effect of BOL-303259-X dosed\n      once daily (QD) with timolol maleate 0.5% dosed twice daily (BID) in reducing intraocular\n      pressure (IOP) measured over a 24-hour period in subjects with open-angle glaucoma (OAG) or\n      ocular hypertension (OHT)."
        }, 
        "brief_title": "BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Ocular Hypertension", 
            "Open Angle Glaucoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must have a diagnosis of OAG or OHT in 1 or both eyes.\n\n          -  Subjects who are treatment-na\u00efve must meet the following IOP requirements at Visit 1\n             (Screening), and pretreated subjects must meet the following IOP requirements at\n             Visit 2 (Washout): Intraocular pressure \u2265 22 mmHg in at least 1 eye and \u2264 36 mmHg in\n             both eyes.\n\n        Exclusion Criteria:\n\n          -  Subjects who have been exposed to BOL-303259-X within 3 months prior to Visit 1\n             (Screening).\n\n          -  Subjects with a history or presence of chronic generalized systemic disease that the\n             Investigator feels might increase the risk to the subject or confound the results of\n             the study.\n\n          -  Subjects with an irregular daily sleep schedule.\n\n          -  Subjects who are unable to wear sleep monitoring device for 7 days prior to\n             laboratory study.\n\n          -  Subjects with an anticipated need to initiate or modify medication (systemic or\n             topical) that is known to affect IOP.\n\n          -  Subjects for whom concomitant use of medications may interact with the safety or\n             efficacy of a nitric oxide.\n\n          -  Subjects with known hypersensitivity or contraindications to latanoprost or any of\n             the ingredients in the study drugs.\n\n          -  Subjects who are expected to require treatment with ocular or systemic\n             corticosteroids.\n\n          -  Subjects who are in need of any other topical or systemic treatment of OAG or OHT.\n\n          -  Subjects who are unable to discontinue contact lens use during and for 24 hours\n             before the laboratory study.\n\n          -  Subjects with a central corneal thickness greater than 600 \u03bcm in either eye.\n\n          -  Subjects with any condition that prevents reliable applanationtonometry in either\n             eye.\n\n          -  Subjects with advanced glaucoma and subjects with a cup/disc ratio greater than 0.8\n             or a history of split fixation, or a field loss threatening fixation in either eye.\n\n          -  Subjects with previous or active corneal disease.\n\n          -  Subjects with a history of severe dry eye.\n\n          -  Subjects with active optic disc hemorrhage.\n\n          -  Subjects with a history of central/branch retinal vein or artery occlusion.\n\n          -  Subjects with a history of macular edema.\n\n          -  Subjects with very narrow angles and subjects with angle closure, congenital, and\n             secondary glaucoma, and subjects with history of angle closure in either eye.\n\n          -  Subjects with a diagnosis of a clinically significant or progressive retinal disease\n             in either eye.\n\n          -  Subjects with any intraocular infection or inflammation within 3 months prior to\n             Visit 1 (Screening).\n\n          -  Subjects with a history of ocular laser surgery within the 3 months prior to Visit 1\n             (Screening).\n\n          -  Subjects with a history of incisional ocular surgery or severe trauma within 3 months\n             prior to Visit 1 (Screening)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01707381", 
            "org_study_id": "803"
        }, 
        "intervention": [
            {
                "arm_group_label": "BOL-303259-X", 
                "description": "Topical ophthalmic solution", 
                "intervention_name": "BOL-303259-X", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Timolol Maleate", 
                "description": "Topical ophthalmic solution", 
                "intervention_name": "Timolol maleate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Timolol", 
                "Maleic acid"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "La Jolla", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92093"
                }, 
                "name": "University of California San Diego"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Single-Center, Open-Label, Crossover Study Comparing the Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension.", 
        "overall_official": {
            "affiliation": "Bausch & Lomb Incorporated", 
            "last_name": "Quintus Ngumah, OD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "IOP measured in the study eye following 4 weeks of treatment", 
            "measure": "IOP", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01707381"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Ocular Perfusion Pressure (OPP)(1/3 systolic blood pressure + 2/3 diastolic blood pressure) \u00d7 2/3 - IOP.", 
                "measure": "Ocular Perfusion Pressure", 
                "safety_issue": "No", 
                "time_frame": "4 weeks and 8 weeks"
            }, 
            {
                "description": "The Area Under the Curve(AUC) is the weighted average of IOP over the total IOP assessment time. The AUC will be calculated using the trapezoidal rule.", 
                "measure": "Area Under the Curve", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }
        ], 
        "source": "Bausch & Lomb Incorporated", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bausch & Lomb Incorporated", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}